Laura Brooks

Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies

Gerard J. Criner, Bartolomé R. Celli, Dave Singh et al. · The Lancet Respiratory Medicine · 2019 · 110 citations · Full text

Translational Medicine, Terranova Studies, Inflammatory Lung Disease +5

Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis

Marc E. Rothenberg, Evan S. Dellon, Margaret H. Collins et al. · New England Journal of Medicine · 2024 · 78 citations

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

Juliane M. Jürgensmeier, Hans‐Joachim Schmoll, Jane Robertson et al. · British Journal of Cancer · 2013 · 64 citations · Full text

Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

Matt Lechner, Yoko Takahashi, Mario Turri–Zanoni et al. · European Journal of Cancer · 2021 · 49 citations · Full text

Neuro-oncology, Medicine, Pathology +4

<p>Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma</p>

J. Mark FitzGerald, Eugene R. Bleecker, Arnaud Bourdin et al. · Journal of Asthma and Allergy · 2019 · 43 citations · Full text